TIGIT competes with CD226 to bind to PVR (CD155) and Nectin-2 (CD112) two molecules often up-regulated on tumor cells thus playing an important role in the NK-cell activity inhibition in part counterbalanced by the co-stimulatory activity exert by DNAM-1(CD226) receptor [33,34]. Here, NECTIN2 is linked to neoplasm.